Cargando…

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients

BACKGROUND: High-grade serous ovarian cancer (HGSOC) has poor survival rates due to a combination of diagnosis at advanced stage and disease recurrence as a result of chemotherapy resistance. In BRCA1 (Breast Cancer gene 1) - or BRCA2-wild type (BRCAwt) HGSOC patients, resistance and progressive dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buttarelli, Marianna, Ciucci, Alessandra, Palluzzi, Fernando, Raspaglio, Giuseppina, Marchetti, Claudia, Perrone, Emanuele, Minucci, Angelo, Giacò, Luciano, Fagotti, Anna, Scambia, Giovanni, Gallo, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815250/ https://www.ncbi.nlm.nih.gov/pubmed/35120576 http://dx.doi.org/10.1186/s13046-022-02265-w

Ejemplares similares

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
por: Buttarelli, Marianna, et al.
Publicado: (2020)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
por: Perrone, Emanuele, et al.
Publicado: (2022)

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
por: Ciucci, Alessandra, et al.
Publicado: (2022)

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers
por: Ciucci, Alessandra, et al.
Publicado: (2016)

KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
por: De Donato, Marta, et al.
Publicado: (2020)

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
por: Raspaglio, Giuseppina, et al.
Publicado: (2021)

A commentary on the discrepancy between blood and tumour BRCA testing: An open question
por: De Paolis, Elisa, et al.
Publicado: (2022)

Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation
por: De Paolis, Elisa, et al.
Publicado: (2021)

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer
por: Buttarelli, Marianna, et al.
Publicado: (2019)

BRCA testing delay during the COVID-19 pandemic: How to act?
por: Minucci, Angelo, et al.
Publicado: (2020)

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report
por: Buttitta, Fiamma, et al.
Publicado: (2023)

Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
por: Nero, Camilla, et al.
Publicado: (2022)

BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic
por: Minucci, Angelo, et al.
Publicado: (2020)

A Computational Framework for Comprehensive Genomic Profiling in Solid Cancers: The Analytical Performance of a High-Throughput Assay for Small and Copy Number Variants
por: Giacò, Luciano, et al.
Publicado: (2022)

High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report
por: Costella, Alessandra, et al.
Publicado: (2018)

The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer
por: Masi, Ilenia, et al.
Publicado: (2023)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

Evaluating the Risk of Inguinal Lymph Node Metastases before Surgery Using the Morphonode Predictive Model: A Prospective Diagnostic Study in Vulvar Cancer Patients
por: Fragomeni, Simona Maria, et al.
Publicado: (2023)

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
por: Lampert, Erika J, et al.
Publicado: (2020)

Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival
por: Ciucci, Alessandra, et al.
Publicado: (2013)

Potent immunogenicity in BRCA1‐mutated patients with high‐grade serous ovarian carcinoma
por: Dai, Ying, et al.
Publicado: (2018)

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2
por: Clarfield, Lauren, et al.
Publicado: (2022)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

Preliminary molecular evidence associating a novel BRCA1 synonymous variant with hereditary ovarian cancer syndrome
por: Minucci, Angelo, et al.
Publicado: (2018)

In search for biomarkers and potential drug targets for uterine serous endometrial cancer
por: Dinoi, Giorgia, et al.
Publicado: (2021)

PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients
por: Battaglia, Alessandra, et al.
Publicado: (2021)

Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements
por: Turashvili, Gulisa, et al.
Publicado: (2020)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer
por: Martinelli, Enrica, et al.
Publicado: (2018)

A Whole Germline BRCA2 Gene Deletion: How to Learn from CNV In Silico Analysis
por: Scaglione, Giovanni Luca, et al.
Publicado: (2018)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients
por: Ji, Gang, et al.
Publicado: (2021)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography
por: Sobecki, Janelle N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_em81hr10vlovaahr763vdrlvip